AbbVie’s big-selling Humira will face competition from at least three biosimilars in Europe in around a year’s time, after the European Commission approved a biosimilar from Boehringer Inge
Novartis and Amgen have expanded an existing collaboration with Arizona’s Banner Alzheimer’s Institute (BAI), and begun a major study investigating whether a BACE1 inhibitor drug can delay
